RecruitingPhase 2NCT06416007

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Sponsor

University of Cincinnati

Enrollment

37 participants

Start Date

Aug 2, 2024

Study Type

INTERVENTIONAL

Conditions

Cancer Metastatic Cancer Locally Advanced Locally Advanced Solid Tumor Locally Advanced Carcinoma

Summary

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

Eligibility

Min Age: 18 Years

Inclusion Criteria9

Solid tumor malignancy with a clinical indication for radiation
Patients must have measurable disease
Target lesion(s) which are amenable to lattice therapy plan
When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy
Age ≥18 years.
ECOG Performance status ≤2
Life expectancy greater than 3 months
Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria6

Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.
Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.
Patients with a history of conditions which predispose them to increased radiation toxicity
Patients with known contraindications to radiation therapy
Patients with uncontrolled intercurrent illness
Pregnant women